-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AyazmJscJ7KwyeGo0usTcM2vvOruG+GUa4ad/qBSckdmhd1xG52rTisdx+RNR9cv
 PtZQeV15k0/Y6sxiK16Mig==

<SEC-DOCUMENT>0001013762-06-000375.txt : 20060215
<SEC-HEADER>0001013762-06-000375.hdr.sgml : 20060215
<ACCEPTANCE-DATETIME>20060215081624
ACCESSION NUMBER:		0001013762-06-000375
CONFORMED SUBMISSION TYPE:	NT 10-Q
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20051231
FILED AS OF DATE:		20060215
DATE AS OF CHANGE:		20060215
EFFECTIVENESS DATE:		20060215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		NT 10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		06619704

	BUSINESS ADDRESS:	
		STREET 1:		9229 WEST SUNSET BOULEVARD, SUITE 830
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069
		BUSINESS PHONE:		3108601362

	MAIL ADDRESS:	
		STREET 1:		9229 WEST SUNSET BLVD, SUITE 830
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90069

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>NT 10-Q
<SEQUENCE>1
<FILENAME>dec31200512b25.txt
<TEXT>
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25

                        Commission File Number: 002-78682


                           NOTIFICATION OF LATE FILING

|_| Form 10-K        |_| Form 11-K          |_| Form 20-F          |X| Form 10-Q
|_| Form N-SAR

         For Period Ended: December 31, 2005

|_| Transition Report on Form 10-K   |_| Transition Report on Form 10-Q
|_| Transition Report on Form 20-F   |_| Transition Report on Form N-SAR

     For the Transition Period Ended: _______________________________________

     Nothing in this form shall be  construed to imply that the  Commission  has
verified any information contained herein.

     If the  notification  relates  to a portion of the  filing  checked  above,
identify the item(s) to which the notification relates:

- ------------------------------------------------------------------------

                                     PART I
                             REGISTRANT INFORMATION

Full name of  registrant  Applied DNA Sciences,  Inc.  Former name if applicable
Address of principal  executive office 25 Health Sciences Drive, Suite 113 City,
state and zip code Stony Brook, New York 11790

                                     PART II
                             RULE 12b-25 (b) AND (c)

     If the subject  report could not be filed  without  unreasonable  effort or
expense and the  registrant  seeks  relief  pursuant  to Rule  12b-25  (b),  the
following should be completed. (Check box if appropriate.)

         |     (a)  The reasons  described in  reasonable  detail in Part III of
         |          this  form  could  not be  eliminated  without  unreasonable
         |          effort or expense;
         |
         |     (b)  The subject annual report,  semi-annual  report,  transition
         |          report on Form 10-K,  20-F,  11-K or Form  10-Q,  or portion
   |X|   |          thereof will be  filed on  or before the  15th  calendar day
         |          following the prescribed due date; or the subject  quarterly
         |          report or transition report on Form 10-Q, or portion thereof
         |          will be filed on or before the fifth  calendar day following
         |          the prescribed due date; and
         |
         |     (c)  The accountant's statement or other exhibit required by Rule
         |          12b-25(c) has been attached if applicable.

                                    PART III
                                    NARRATIVE

     State below in  reasonable  detail the reasons why Form 10-K,  11-K,  20-F,
10-Q,  N-SAR or the transition  report portion thereof could not be filed within
the prescribed time period.

     The compilation, dissemination and review of the information required to be
presented  in the Form 10-QSB for the relevant  fiscal  quarter has imposed time
constraints  that have rendered  timely filing of the Form 10-QSB  impracticable
without undue hardship and expense to the registrant.  The registrant undertakes
the  responsibility  to file such quarterly report no later than five days after
its original due date.

                                     PART IV
                                OTHER INFORMATION

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this
     notification

         James Hayward             (631)                444-6862
           (Name)                (Area Code)        (Telephone Number)

(2) Have all other  periodic  reports  required under Section 13 or 15(d) of the
Securities  Exchange Act of 1934 or Section 30 of the Investment  Company Act of
1940  during  the  preceding  12  months  or for such  shorter  period  that the
registrant was required to file such report(s) been filed?  If the answer is no,
identify report(s).

                                 |X| Yes |_| No

(3) Is it anticipated that any significant  change in results of operations from
the  corresponding  period for the last  fiscal  year will be  reflected  by the
earnings statements to be included in the subject report or portion thereof?

                                 |_| Yes |X| No

If so: attach an explanation of the  anticipated  change,  both  narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.



<PAGE>



                           Applied DNA Sciences, Inc.
                   Name of Registrant as Specified in Charter.

Has  caused  this  notification  to be signed on its  behalf by the  undersigned
thereunto duly authorized.

Dated:  February 15, 2006               /s/ JAMES HAYWARD
                                        -----------------
                                        By: James Hayward
                                        Title: Chief Executive Officer
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
